Johnson & Johnson has its third multiple myeloma product and its second B-cell maturation antigen (BCMA)-targeting therapy in the US with the 25 October approval of Tecvayli (teclistamab-cqyv) for the fifth-line or later treatment of relapsed or refractory myeloma. The product, developed and soon to be launched by J&J’s Janssen Pharmaceutical Cos., marks the next step in the big pharma’s approach to building a multi-drug myeloma franchise.
The list price for Tecvayli will vary from patient to patient but based on the pivotal Phase II MajesTEC-1 clinical trial in which patients were treated on average for nine to 10 months, the product’s cost is expected to be about $355,000-$395,000 or $39,500 per month
